Effects of thick Tenon's capsule on primary trabeculectomy with mitomycin‐C

Akarsu, Cengiz; Önol, Merih; Hasanreısoğlu, Berati

doi:10.1034/j.1600-0420.2003.00069.x

Cited by 13 publications

(5 citation statements)

References 34 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitomycin C is an antineoplastic-antibiotic agent produced by Streptomyces caespitosus that inhibits the synthesis of DNA, proteins and cellular RNA and is a potent inhibitor of fibroblasts proliferation. Drug use has improved not only recurrence rate after pterygium surgery but also the surgical results in other ocular disease, such as glaucoma, or corneal and conjunctival intraepithelial neoplasia 7,8,9 .…”

Section: Introductionmentioning

confidence: 99%

Conjunctival Short-term Evolution after Pterygium Excision

Julio

Lluch

Pujol³

et al. 2015

Optometry and Vision Science

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Conjunctival Short-term Evolution after Pterygium Excision

Julio

Lluch

Pujol³

et al. 2015

Optometry and Vision Science

View full text Add to dashboard Cite

show abstract

“…Histological studies have shown that proliferation of subconjunctival fibroplasts, which is believed to play an important role in bleb failure, occurs during the third to fifth postoperative day (Jampel et al 1988;Pescosolido et al 2002). Adjunctive antimetabolites, such as 5-fluorouracil (5-FU) and mitomycin-C, are commonly used to enhance the success of trabeculectomy (Azuara-Blanco et al 1997;Bindlish et al 2002;Akarsu et al 2003;Beckers et al 2003;Fraser 2004;Cillino et al 2008). However, the use of antimetabolites increases the risks of hypotony, bleb leakage and infection (Jampel et al 1992;Bell et al 1997;Nuijts et al 1997;Singh et al 1997;Spaeth & Mutlukan 2001;Lama & Fechtner 2003).…”

Section: Introductionmentioning

confidence: 99%

Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study

Papaconstantinou

Georgalas

Karmiris

et al. 2010

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To present the preliminary results of our study comparing the outcomes of trabeculectomy with or without OloGen implant in patients requiring glaucoma surgery for uncontrolled intraocular pressure (IOP). Methods: Forty eyes of 40 patients were assigned randomly to undergo trabeculectomy either with OloGen implant (study group) or without implant (control group). Preoperative data included age, gender, type of glaucoma, IOP and number of preoperative glaucoma medications. Postoperative IOP, number of postoperative glaucoma medications and postoperative complications were recorded. Each patient was followed up for at least 6 months. Results: There were no significant differences between the groups in terms of age, gender, type of glaucoma, preoperative IOP and number of antiglaucoma medications. Mean IOPs for both groups were significantly lower than preoperative levels at all intervals (P < 0.05) The number of glaucoma medications used dropped from a preoperative mean of 3.5 ± 0.7 to a 6-month postoperative mean of 0.3 ± 0.7 (P < 0.001) in the study group and from 3.7 ± 0.4 to 0.5 ± 1.1 (P < 0.001) in the control group. No statistically significant differences between the two groups were observed in terms of postoperative complications. Conclusion: In this pilot study it appears that trabeculectomy with OloGen does not seem to offer any significant advantages compared with trabeculectomy alone. Additionally, even though there were no statistical differences between the two groups as far as complications were concerned, one eye from the study group developed endophthalmitis 10 days after surgery and two eyes presented with positive Seidel test and flat anterior chamber and required additional suturing. Studies with larger numbers of patients and longer follow-ups are required to confirm these findings and to examine the safety and long-term outcomes of trabeculectomy with OloGen.

show abstract

“…Pathology studies have shown that, following trabeculectomy, migration, proliferation, and differentiation of the fibroblasts at the subconjunctival level, which are responsible for the fibrotic process and eventually the bleb failure, occur as early as the third to fifth postoperative day [ 8 , 9 ]. Adjunctive antimetabolites, such as 5-fluorouracil (5-FU) and mitomycin C (MMC), both intra- and postoperatively, are commonly used to enhance the long-term success of trabeculectomy [ 10 – 14 ]. However, due to their nonselective cytotoxicity, which could lead to conjunctival barrier breakdown, their use is not free of increased risk of complications, some of them devastating, such as ischemic and leaking bleb which could predispose to serious infections and even endophthalmitis [ 15 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Trabeculectomy with Healaflow versus Trabeculectomy for the Treatment of Glaucoma: A Case-Control Study

Papaconstantinou

Diagourtas

Petrou

et al. 2015

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To compare the outcomes of trabeculectomy with and without Healaflow (Anteis S.A, Geneva, Switzerland), a high molecular weight viscoelastic gel, in patients requiring glaucoma surgery. Methods. This was a retrospective, comparative, interventional case-control study. Forty patients formed two matched study groups and were analyzed (trabeculectomy alone (control) versus trabeculectomy with Healaflow (study)). Results. The postoperative levels of mean IOP were statistically significantly lower (P < 0.05) than preoperatively in both groups, for all time intervals. There was no statistical difference, at the end of the follow-up period, between the two groups in the mean values of the IOP (14.9 ± 3.2 mmHg for the study group versus 14.8 ± 3.3 mmHg for the control group). The number of antiglaucoma drugs used in the study group was reduced from a preoperative mean of 3.4 ± 0.75 to a 6-month postoperative mean of 0.6 ± 0.8 (P < 0.001) and in the control group from 3.6 ± 0.59 to 0.55 ± 0.9 (P < 0.001). Conclusions. Although trabeculectomy with Healaflow appears to be a safe procedure, we failed to identify any significant advantages in the use of Healaflow when compared with trabeculectomy alone, at the end of the 6-month follow-up period.

show abstract

Effects of thick Tenon's capsule on primary trabeculectomy with mitomycin‐C

Abstract: The use of mitomycin-C is associated with high success rates and good IOP control even in the presence of thick Tenon's capsule. However, thick Tenon's capsule does not seem to eliminate the development of complications in eyes undergoing primary trabeculectomy with mitomycin-C.

Cited by 13 publications

References 34 publications

Conjunctival Short-term Evolution after Pterygium Excision

Conjunctival Short-term Evolution after Pterygium Excision

Trabeculectomy with OloGen versus trabeculectomy for the treatment of glaucoma: a pilot study

Trabeculectomy with Healaflow versus Trabeculectomy for the Treatment of Glaucoma: A Case-Control Study

Contact Info

Product

Resources

About